All In Biotech

Drug Trial Radar · NCT06270706

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on an Immune Checkpoint Inhibitor (FORTIFY)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

124

Planned (sponsor's estimate)

Start

Aug 30, 2023

Primary completion

Jun 2030

Study completion Jun 2030

Sponsor

Lead sponsor
Pliant Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory \[primary resistance\]) or relapsed \[secondary resistance\]) after at least 3 months from the start of treatment with pembrolizumab. The study will consist of 2 main parts: * Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration * Part 2: Dose-expansion cohorts using Simon's 2-stage design

Conditions

  • Advanced or Metastatic Solid Tumor

Interventions

  • PLN-101095Drug

    PLN-101095 250 mg BID

  • PLN-101095Drug

    PLN-101095 500 mg BID

  • PLN-101095Drug

    PLN-101095 1000 mg BID

  • PLN-101095Drug

    PLN-101095 1000 mg TID

  • PLN-101095Drug

    PLN-101095 2000 mg BID

  • PLN-101095Drug

    PLN-101095

  • PembrolizumabDrug

    Pembrolizumab (KEYTRUDA) 200 mg IV Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2Time frame: First dose to 35 days
  2. Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2Time frame: Day 1 until 16 weeks after end of study treatment regimen
  3. Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2Time frame: First dose to disease progression or death from any cause, whichever occurs first.
  4. Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2Time frame: First dose to disease progression or death from any cause, whichever occurs first.

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • Yale University

    New Haven, Connecticut · Completed

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • South Texas Accelerated Research Therapeutics (START)

    Grand Rapids, Michigan · Recruiting

  • Washington University Medicine

    St Louis, Missouri · Recruiting

  • START New Jersey

    East Brunswick, New Jersey · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • START New York Long Island LLC

    Lake Success, New York · Recruiting

  • Carolina Cancer Research Center

    Wilson, North Carolina · Recruiting

  • Avera Medical Group

    Sioux Falls, South Dakota · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • NEXT Austin

    Austin, Texas · Recruiting

  • START Center for Clinical Research

    Fort Worth, Texas · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Houston

    Houston, Texas · Recruiting

  • UT Health San Antonio's Mays Cancer Center

    San Antonio, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • Inova Schar Cancer Institute

    Fairfax, Virginia · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Swedish Cancer Institute Medical Oncology

    Edmonds, Washington · Recruiting

  • Hospital Universitari Quirónsalud (NEXT Barcelona)

    Barcelona, Barcelona, Spain · Recruiting

  • START Barcelona - Hospital HM Nou Delfos

    Barcelona, Barcelona, Spain · Recruiting

  • Hospital Universitari Vall d'Hebron - VHIO

    Barcelona, Barcelona, Spain · Recruiting

  • START Center for Cancer Research - La Rioja

    Logroño, La Rioja, Spain · Recruiting

  • START Madrid - Hospital Universitario Fundación Jiménez Díaz

    Madrid, Madrid, Spain · Recruiting

  • START Madrid - Centro Integral Oncológico Clara Campal

    Madrid, Madrid, Spain · Recruiting

  • University Hospital Quironsalud Madrid (NEXT Madrid)

    Madrid, Pozuelo de Alarcón, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.